Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.57 |
| ▸ | FADS1 | O60427 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2682054 | 0.85 | KMT2A (1.00) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL11457921 | 0.84 | GPR35 (0.60) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL1884170 | 0.83 | MEN1 (0.74) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL11066912 | 0.83 | MEN1 (0.74) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL23447836 | 0.82 | MEN1 (0.71) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL5141417 | 0.82 | MEN1 (0.71) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL167193 | 0.82 | MEN1 (0.71) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL10956636 | 0.82 | MEN1 (0.71) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL357999 | 0.82 | MEN1 (0.71) | MEN1KMT2ALMNAMAPTHTT | |
| SCHEMBL11260240 | 0.82 | MEN1 (0.71) | MEN1KMT2ALMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5238909-A | For preemergence or postemergence use | EASTMAN KODAK COMPANY (US) | 1993-08-24 | — | — | US | claimed |
| EP-0476760-A2 | 4-substituted isoxazole herbicides | EASTMAN KODAK COMPANY (US) | 1992-03-25 | — | — | EP | claimed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5770734-A | N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| US-5238909-A | For preemergence or postemergence use | EASTMAN KODAK COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0476760-A2 | 4-substituted isoxazole herbicides | EASTMAN KODAK COMPANY (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0308284-B1 | 1,2,5,6-TETRAHYDROPYRIDINE OXIME DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1992-03-11 | — | — | EP | disclosed |
| EP-0308284-A1 | 1,2,5,6-Tetrahydropyridine oxime derivatives, process for their preparation, their use as pharmaceutical compounds and compositions containing them | ROUSSEL-UCLAF (FR) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MEN1 4525/4885KMT2A 3324/4885LMNA 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.